Is TransMedics Group Inc (TMDX) overvalued? · P/E 17, rev $363.9M
TransMedics Group Inc (TMDX) is a medical devices company listed on NASDAQ.
This page asks whether TransMedics Group Inc (TMDX) looks expensive on cached numbers — not a short thesis.
Latest reported TMDX revenue for 2026-06-30 was $363.9M. Net income was $22.0M. TMDX currently screens at market cap $2.53B and trailing P/E 16.8.
TMDX currently screens at market cap $2.53B and trailing P/E 16.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TMDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TMDX stock page for the full model, not this heading.
Not investment advice.